We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Becton Dickinson (BDX) Reports Q2 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
For the quarter ended March 2025, Becton Dickinson (BDX - Free Report) reported revenue of $5.27 billion, up 4.5% over the same period last year. EPS came in at $3.35, compared to $3.17 in the year-ago quarter.
The reported revenue represents a surprise of -1.74% over the Zacks Consensus Estimate of $5.37 billion. With the consensus EPS estimate being $3.28, the EPS surprise was +2.13%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenues- BD Life Sciences- Biosciences- United States: $142 million versus $145.02 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
Revenues- BD Medical- Medication Delivery Solutions- United States: $687 million versus $703.87 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.8% change.
Revenues- BD Interventional- International: $384 million versus the four-analyst average estimate of $394.64 million. The reported number represents a year-over-year change of -2.8%.
Revenues- BD Interventional- United States: $880 million versus the four-analyst average estimate of $913.82 million. The reported number represents a year-over-year change of -2%.
Revenues- BD Interventional: $1.26 billion versus the five-analyst average estimate of $1.31 billion. The reported number represents a year-over-year change of -2.2%.
Revenues- BD Interventional- Surgery: $383 million versus $393.29 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.1% change.
Revenues- BD Interventional- Peripheral Intervention: $481 million versus $499.49 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -1.6% change.
Revenues- BD Interventional- Urology and Critical Care: $400 million versus $413.17 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.7% change.
Revenues- BD Medical- Advanced Patient Monitoring [$M]: $257 million versus the five-analyst average estimate of $261.87 million.
Revenues- BD Medical: $2.76 billion versus the five-analyst average estimate of $2.77 billion. The reported number represents a year-over-year change of +12.7%.
Revenues- BD Medical- Medication Delivery Solutions: $1.12 billion versus $1.15 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change.
Revenues- BD Life Sciences- Biosciences: $352 million compared to the $363.86 million average estimate based on five analysts. The reported number represents a change of -6.6% year over year.
Shares of Becton Dickinson have returned -8.5% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Becton Dickinson (BDX) Reports Q2 Earnings: What Key Metrics Have to Say
For the quarter ended March 2025, Becton Dickinson (BDX - Free Report) reported revenue of $5.27 billion, up 4.5% over the same period last year. EPS came in at $3.35, compared to $3.17 in the year-ago quarter.
The reported revenue represents a surprise of -1.74% over the Zacks Consensus Estimate of $5.37 billion. With the consensus EPS estimate being $3.28, the EPS surprise was +2.13%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Becton Dickinson performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- BD Life Sciences- Biosciences- United States: $142 million versus $145.02 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a 0% change.
- Revenues- BD Medical- Medication Delivery Solutions- United States: $687 million versus $703.87 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +3.8% change.
- Revenues- BD Interventional- International: $384 million versus the four-analyst average estimate of $394.64 million. The reported number represents a year-over-year change of -2.8%.
- Revenues- BD Interventional- United States: $880 million versus the four-analyst average estimate of $913.82 million. The reported number represents a year-over-year change of -2%.
- Revenues- BD Interventional: $1.26 billion versus the five-analyst average estimate of $1.31 billion. The reported number represents a year-over-year change of -2.2%.
- Revenues- BD Interventional- Surgery: $383 million versus $393.29 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +1.1% change.
- Revenues- BD Interventional- Peripheral Intervention: $481 million versus $499.49 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -1.6% change.
- Revenues- BD Interventional- Urology and Critical Care: $400 million versus $413.17 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -5.7% change.
- Revenues- BD Medical- Advanced Patient Monitoring [$M]: $257 million versus the five-analyst average estimate of $261.87 million.
- Revenues- BD Medical: $2.76 billion versus the five-analyst average estimate of $2.77 billion. The reported number represents a year-over-year change of +12.7%.
- Revenues- BD Medical- Medication Delivery Solutions: $1.12 billion versus $1.15 billion estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +0.9% change.
- Revenues- BD Life Sciences- Biosciences: $352 million compared to the $363.86 million average estimate based on five analysts. The reported number represents a change of -6.6% year over year.
View all Key Company Metrics for Becton Dickinson here>>>Shares of Becton Dickinson have returned -8.5% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.